NEW YORK , July 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics , Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced presentations covering the

On July 1, 2020, a fraudulent “short report” was posted. The fraudulent report includes manipulated company graphs and figures, fraudulent misrepresentation of data, and factual misstatements. Applied Therapeutics will work with law enforcement and regulators to ensure this criminal stock

AT-007 pediatric Galactosemia study (ACTION-Galactosemia Kids) initiated Additional 40mg/kg adult cohort demonstrates incremental efficacy; data reinforces AT-007 favorable safety and efficacy profile NEW YORK , June 15, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics , Inc. (Nasdaq: APLT), a

NEW YORK , June 08, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that three abstracts have

NEW YORK , June 03, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at

NEW YORK , May 26, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today the appointment of Dr.

NEW YORK , May 12, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the

NEW YORK , May 11, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the

AT-007 demonstrated rapid and sustained reduction in toxic galactitol levels with no accompanying increase in galactose Positive trend on MRI outcomes, including indirect measures of edema, neuronal health and brain galactitol levels in AT-007-treated patients 40 mg/kg dose of AT-007 was

New AT-001 IND opened with FDA for acute lung inflammation and cardiomyopathy in critical COVID-19 patients Hospitals in New York City have commenced investigator-initiated studies; additional programs expected NEW YORK , April 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc.